Selective estrogen receptor modulators in clinical practice: A safety overview

Expert Opinion on Drug Safety

Volumn 14, Issue 6, 2015, Pages 921-934

  Ellis, Amanda J ^a   Hendrick, Vicky M ^a   Williams, Robert ^b   Komm, Barry S ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Bazedoxifene; Fulvestrant; Lasofoxifene; Ospemifene; Raloxifene; Safety; Selective estrogen receptor modulator; Tamoxifen; Toremifene

Indexed keywords

BAZEDOXIFENE; ESTROGEN RECEPTOR; FULVESTRANT; LASOFOXIFENE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSPEMIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; TRIACYLGLYCEROL; ANTIESTROGEN; ESTROGEN;

ABNORMAL LABORATORY RESULT; ANTIPROLIFERATIVE ACTIVITY; ARTHRALGIA; ARTHROPATHY; ATRIAL FIBRILLATION; BREAST CALCIFICATION; BREAST CANCER; BREAST TUMOR; CARDIOVASCULAR DISEASE; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPAREUNIA; ENDOMETRIAL DYSPLASIA; ENDOMETRIAL THICKNESS; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ENDOMETRIUM TUMOR; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC DISEASE; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERHIDROSIS; ISCHEMIC HEART DISEASE; LEG CRAMP; LUNG EMBOLISM; MENOPAUSAL SYNDROME; MENOPAUSE; MUSCLE CRAMP; OVARY CARCINOMA; OVARY CYST; PATIENT MONITORING; PATIENT SELECTION; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINAL VEIN THROMBOSIS; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TACHYCARDIA; THROMBOEMBOLISM; THROMBOPHLEBITIS; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; VAGINA BLEEDING; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VASOMOTOR DISORDER; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; BREAST NEOPLASMS; DRUG MONITORING; FEMALE; OSTEOPOROSIS, POSTMENOPAUSAL;

BREAST NEOPLASMS; DRUG MONITORING; DYSPAREUNIA; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SELECTION; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84929584092     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1014799     Document Type: Review

References (66)

1. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29 .. Comprehensive review article on selective oestrogen receptor modulator mechanism of action and clinical applications.
2. Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 1977;75:305-16
3. Osborne CK, Boldt DH, Clark GM, Trent JM. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 1983;43:3583-5
4. Nolvadex [package insert]. AstraZeneca Pharmaceuticals LP; Wilmington, DE: 2007
5. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifentreated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37
6. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97
7. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7
8. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45
9. Evista [package insert]. Eli Lilly and Co; Indianapolis, IN: 2011
10. Harvey HA, Kimura M, Hajba A. Toremifene: an evaluation of its safety profile. Breast 2006;15:142-57 . Comprehensive review article on the safety of toremifene.
11. Michael H, Harkonen PL, Kangas L, et al. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol 2007;151:384-95
12. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-8
13. Karlsson S, Iatropoulos MJ, Williams GM, et al. The proliferation in uterine compartments of intact rats of two different strains exposed to high doses of tamoxifen or toremifene. Toxicol Pathol 1998;26:759-68
14. Chatterjee M, Harris AL. Enhancement of Adriamycin cytotoxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-Adrr, by toremifene and its modulation by alpha 1 acid glycoprotein. Eur J Cancer 1990;26:432-6
15. Fareston [package insert]. ProStrakan Inc; Bridgewater, NJ: 2012
16. Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008 .. Preclinical characteristics of bazedoxifene compared to raloxifene.
17. Lewis-Wambi JS, Kim H, Curpan R, et al. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. Mol Pharmacol 2011;80:610-20
18. Rosati RL, Da Silva JP, Cameron KO, et al. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 1998;41:2928-31
19. European Medicines Agency. Assessment report for fablyn. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-Assessment-report/human/000977/WC500020096.pdf [Last accessed 23 January 2014]
20. Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000;141:809-20
21. Osphena [package insert]. Shionogi Inc; Florham Park, NJ: 2013
22. European Medicines Agency. CHMP summary of positive opinion for senshio. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial-Authorisation/human/002780/WC500177633.pdf [Last accessed 15 January 2015]
23. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 2000;89:817-25
24. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106(Pt 4):1377-88
25. Wardell SE, Marks JR, McDonnell DP. The turnover of estrogen receptor alpha by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem Pharmacol 2011;82:122-30
26. European Medicines Agency. Summary of product characteristics: faslodex. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000540/WC500021174.pdf [Last accessed 23 January 2014]
27. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88 . First report on tamoxifen data for breast cancer.
28. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24
29. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37 . Key safety data for raloxifene.
30. Christiansen C, Chesnut CH III, Adachi JD, et al. Safety of bazedoxifene in a randomized, double-blind, placeboand active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 2010;11:130
31. de Villiers TJ, Chines AA, Palacios S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011;22:567-76
32. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and activecontrolled study. J Bone Miner Res 2008;23:525-35
33. LaCroix AZ, Powles T, Osborne CK, et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 2010;102:1706-15
34. Simon JA, Lin VH, Radovich C, Bachmann GA. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013;20:418-27 . Long-term safety of ospemifene.
35. Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623-30
36. Martino S, Disch D, Dowsett SA, et al. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 2005;21:1441-52
37. Pyrhonen S, Valavaara R, Modig H, et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study. Br J Cancer 1997;76:270-7
38. Gershanovich M, Garin A, Baltina D, et al. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res Treat 1997;45:251-62
39. Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995;13:2556-66
40. Pagani O, Gelber S, Price K, et al. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 2004;15:1749-59
41. Palacios S, de Villiers TJ, Nardone FC, et al. Assessment of the safety of longterm bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study. Maturitas 2013;76:81-7 . Long-term safety of bazedoxifene.
42. Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480-6
43. Morales L, Neven P, Timmerman D, et al. Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant. Breast Cancer Res Treat 2009;117:77-81
44. Soltamox [package insert]. Savient Pharmaceuticals, Inc; East Brunswick, NJ: 2005
45. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-82
46. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61
47. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41
48. Chi F, Wu R, Zeng Y, et al. Effects of toremifene versus tamoxifen on breast cancer patients: a meta-Analysis. Breast Cancer 2013;20:111-22
49. Vogel CL, Johnston MA, Capers C, Braccia D. Toremifene for breast cancer: a review of 20 years of data. Clin Breast Cancer 2014;14:1-9
50. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and activecontrolled clinical trial. J Bone Miner Res 2008;23:1923-34
51. Silverman SL, Chines AA, Kendler DL, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2012;23:351-63
52. Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009;16:1109-15
53. Pinkerton JV, Archer DF, Utian WH, et al. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 2009;16:1102-8
54. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-96
55. Goldstein SR, Neven P, Cummings S, et al. Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes. Menopause 2011;18:17-22
56. Ensrud K, LaCroix A, Thompson JR, et al. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation 2010;122:1716-24
57. Fong K, Causer P, Atri M, et al. Transvaginal US and hysterosonography in postmenopausal women with breast cancer receiving tamoxifen: correlation with hysteroscopy and pathologic study. Radiographics 2003;23:137-50
58. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-38
59. Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605-13
60. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594-600
61. Duvernoy CS, Kulkarni PM, Dowsett SA, Keech CA. Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene. Menopause 2005;12:444-52
62. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51
63. Euser AM, Zoccali C, Jager KJ, Dekker FW. Cohort studies: prospective versus retrospective. Nephron Clin Pract 2009;113:c214-17
64. European Medicine Agency. Summary of product characteristics. Conbriza. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000913/WC500033577.pdf [Last accessed 19 December 2013]
65. Palacios S, Silverman SL, de Villiers TJ, et al. A 7-year, randomized, placebocontrolled trial to assess the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause 2015. [Epub ahead of print]
66. Study evaluating bazedoxifene acetate in osteoporosis in postmenopausal women NCT00205777. ClinicalTrials.gov Available from: http://www.clinicaltrials. gov/ct2/show/study/NCT00205777? term=3068A1-301&rank=2§=X30156 [Last accessed 20 November 2014]